natgillin/translations-raw huggingface dataset:
You should not use Nevirapine Teva on its own. 
Nevirapin Teva se ne smije primjenjivati sam.
No specific drug-drug interaction study has been performed. 
Nisu provedena specifična interakcijska ispitivanja.
Nevirapine Cmin ↓ 0.32 
Nevirapin Cmin ↓ 0,32
Nevirapine Teva contains lactose 
Nevirapin Teva sadrži laktozu
Furthermore, combining the following compounds with Nevirapine Teva is not recommended: efavirenz, ketoconazole, delavirdine, etravirine, rilpivirine, elvitegravir (in combination with cobicistat), atazanavir (in combination with ritonavir), boceprevir; fosamprenavir (if not co-administered with low dose ritonavir) (see section 4.5). 
ketokonazol, delavirdin, etravirin, rilpivirin, elvitegravir (u kombinaciji s kobicistatom), atazanavir (u kombinaciji s ritonavirom), boceprevir, fosamprenavir (ako se primjenjuje istovremeno uz nisku dozu ritonavira) (vidjeti dio 4.5).
If you stop taking Nevirapine Teva 
Ako prestanete uzimati Nevirapin Teva
Hepatic dysfunction: A steady state study comparing 46 patients with mild (n=17: Ishak Score 1-2), moderate (n=20; Ishak Score 3-4), or severe (n=9; Ishak Score 5-6, Child-Pugh A in 8 pts., for 1 Child-Pugh score not applicable) liver fibrosis as a measure of hepatic impairment was conducted. 
Disfunkcija jetre: Provedeno je ispitivanje u stanju dinamičke ravnoteže u 46 bolesnika s blagom (n=17; Ishak indeks 1-2), umjerenom (n=20; Ishak indeks 3-4), ili teškom (n=9; Ishak indeks 5-6, Child Pugh A u 8 bolesnika, za jednoga Child Pugh indeks nije primjenjiv)
Patients should be instructed that a major toxicity of nevirapine is rash. 
Bolesnike je potrebno upozoriti da je osip važna manifestacija toksičnosti nevirapina.
Therefore coadministration would likely result in altered plasma levels of cobicistat and Nevirapine Teva. 
Stoga bi istodobna primjena vjerojatno rezultirala promijenjenim vrijednostima kobicistata i Nevirapina Teva u plazmi.
Check with your doctor or pharmacist if you are not sure. 
Uvijek uzimajte ovaj lijek točno onako kako Vam je rekao liječnik Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni.
Nevirapine is contraindicated in patients with severe hepatic impairment (Child-Pugh C, see section 4.3). 
Nevirapin je kontraindiciran u bolesnika s teškim jetrenim poremećajima (Child-Pugh C, vidjeti dio 4.3.).
Caution should be exercised when prescribing nevirapine to pregnant women (see section 4.4). 
Stoga je nužan oprez u propisivanju nevirapina trudnicama (vidjeti dio 4.4.).
Nevirapine Teva should be administered by physicians who are experienced in the treatment of HIV infection. 
Nevirapin Teva moraju primjenjivati liječnici s iskustvom u liječenju HIV-infekcije.
Oral hormonal contraceptives should not be used as the sole method of contraception in women taking Nevirapine Teva (see section 4.4). 
Oralni hormonski kontraceptivi ne smiju se primjenjivati kao jedina metoda kontracepcije u žena koje uzimaju Nevirapin Teva (vidjeti dio
At 12 months, the Kaplan-Meier estimates of the likelihood of reaching the endpoint were 10 % in the nevirapine group, 6 % in the efavirenz group, and 13 percent in the abacavir group (P=0.10 according to an intention-to-treat analysis). 
Vjerojatnost postizanja primarnog ishoda nakon 12 mjeseci liječenja, procjena po Kaplan-Meieru, bila je 10% za nevirapin, 6% za efavirenz i 13% za abakavir (p=0,10 prema ITT analizi).
Nevirapine co-administration did not alter the ovulation suppression effects of DMPA. 
Istodobna primjena nevirapina nije promijenila učinke ovulacijske supresije DMPA.
Nevirapine metabolites: Studies using human liver microsomes indicated that the formation of nevirapine hydroxylated metabolites was not affected by the presence of dapsone, rifabutin, rifampicin, and trimethoprim/sulfamethoxazole. 
Metaboliti nevirapina: Ispitivanja na mikrosomima ljudske jetre pokazale su da dapson, rifabutin, rifampicin i trimetroprim/sulfametoksazol nisu utjecali na stvaranje hidroksiliranih metabolita nevirapina, dok su ketokonazol i eritromicin značajno inhibirali njihovo stvaranje.
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept. (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
Fertility In reproductive toxicology studies, evidence of impaired fertility was seen in rats. 
U ispitivanjima reproduktivne toksičnosti kod štakora su uočeni poremećaji plodnosti.
1,216 antiretroviral-therapy naïve patients with plasma HIV-1 RNA > 5,000 copies/ml at baseline were assigned to nevirapine 400 mg once daily, nevirapine 200 mg twice daily, efavirenz 600 mg once daily, or nevirapine (400 mg) and efavirenz (800 mg) once daily, plus stavudine and lamivudine for 48 weeks. 
kopija/ml primali su nevirapin 400 mg jednom dnevno, nevirapin 200 mg dvaput dnevno, efavirenz 600 mg jednom dnevno ili nevirapin (400 mg) i efavirenz (800 mg) jednom dnevno, plus stavudin i lamivudin tijekom 48 tjedana.
Patients experiencing rash during the 14-day lead-in period of 200 mg/day should not have their Nevirapine Teva dose increased until the rash has resolved. 
Na što treba paziti u doziranju Bolesnicima kod kojih se tijekom 14-dnevnog uvodnog razdoblja uz dozu od 200 mg/dan pojavi osip ne smiju povećavati dozu Nevirapina Teva dok se osip ne povuče.
These events are commonly associated with other antiretroviral agents and may be expected to occur when Nevirapine Teva is used in combination with other agents; however, it is unlikely that these events are due to treatment with Nevirapine Teva. 
Ovi slučajevi često se vežu za druge antiretrovirusne lijekove te se njihova pojava može očekivati kada se Nevirapin Teva primjenjuje u kombinaciji s drugim lijekovima; međutim, ne čini se da su ovakvi slučajevi uzrokovani liječenjem Nevirapinom Teva.
Nevirapine belongs to a class of anti-HIV medicines called non-nucleoside reverse transcriptase inhibitors (NNRTIs). 
Nevirapin pripada skupini lijekova koji djeluju protiv virusa humane imunodeficijencije (HIV), a zovu se nenukleozidni inhibitori reverzne transkriptaze (NNRTI).
Enfuvirtide 
Enfuvirtid
You should stop breast-feeding if you are taking Nevirapine Teva. 
Potrebno je prekinuti dojenje ako uzimate Nevirapin Teva.
It allows continued monitoring of the benefit/risk balance of the medicinal product. 
Time se omogućuje kontinuirano praćenje omjera koristi i rizika tog lijeka.
How to take Nevirapine Teva 
Kako uzimati Nevirapin Teva
Reporting suspected adverse reactions after authorisation of the medicinal product is important. 
Nakon odobrenja lijeka, važno je prijavljivanje sumnji na njegove nuspojave.
An increased risk was observed in men with detectable HIV-1 RNA in plasma and CD4 counts > 400 cells/mm3 (6.3 % versus 1.2 % for men with CD4 counts < 400 cells/mm3). 
Povećan rizik primijećen je u muškaraca s detektabilnom HIV-1 RNK u plazmi i brojem CD4 >400 stanica/mm3 (6,3% naspram
If a patient is already taking St. John‘s Wort check nevirapine and if possible viral levels and stop St John‘s Wort. 
Ako bolesnik već uzima gospinu travu, valja provjeriti koncentracije nevirapina i ako je moguće broj virusnih razina te prekinuti primjenu gospine trave.
- if you have taken Nevirapine Teva before and had to stop the treatment because you suffered from: - severe skin rash - skin rash with other symptoms for example: - fever - blistering - mouth sores - inflammation of the eye - swelling of the face - general swelling - shortness of breath 
- ako ste prije uzimali Nevirapin Teva te ste morali prekinuti liječenje jer ste patili od: - teškog kožnog osipa - kožnog osipa s drugim simptomima, na primjer:
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions. 
C koji se liječe kombiniranom antiretrovirusnom terapijom su pod povećanim rizikom od teških i potencijalno fatalnih jetrenih nuspojava.
For patients with renal dysfunction requiring dialysis an additional 200 mg dose of nevirapine following each dialysis treatment is recommended. 
Za bolesnike s bubrežnom disfunkcijom koja zahtijeva dijalizu, preporučuje se dodatna doza od 200
Prednisone should not be used to treat a rash related to Nevirapine Teva. 
Prednizon se ne smije primjenjivati u liječenju osipa povezanog s Nevirapinom Teva.
If a dose is missed and it is more than 8 hours later, the patient should only take the next dose at the usual time. 
Ako je doza propuštena, a prošlo više od 8 sati, treba uzeti sljedeću dozu u uobičajeno vrijeme.
Non-clinical data reveal no special hazard for humans other than those observed in clinical studies based on conventional studies of safety, pharmacology, repeated dose toxicity, and genotoxicity. 
Neklinički podaci temeljeni na konvencionalnim ispitivanjima sigurnosti, farmakologije, toksičnosti ponovljenih doza i genotoksičnosti nisu ukazali na posebne opasnosti za ljude osim onih opaženih u kliničkim ispitivanjima.
If co-administered with Nevirapine Teva, an adjustment in the telaprevir dose should be considered. 
Ako se uzima istodobno s Nevirapinom Teva, potrebno je razmotriti prilagodbu doze telaprevira.
The following adverse reactions which may be causally related to the administration of nevirapine have been reported. 
Prijavljeno je da sljedeće nuspojave mogu biti uzročno povezane s primjenom nevirapinom.
No drug-drug interaction study of telaprevir with nevirapine has been conducted, however, interaction studies of telaprevir with an NNRTI with a similar metabolic pathway as nevirapine demonstrated reduced levels of both. 
Međutim, ispitivanja interakcija telaprevira s NNRTI-om sa sličnim metaboličkim putem nevirapinu su pokazala smanjene vrijednosti koncentracije oba lijeka.
As serious and life threatening hepatotoxicity has been observed in controlled and uncontrolled studies predominantly in patients with a plasma HIV-1 viral load of 50 copies/ml or higher, nevirapine should not be initiated in adult females with CD4 cell counts greater than 250 cells/mm3 or in adult males with CD4 cell counts greater than 400 cells/mm3, who have a detectable plasma HIV-1 RNA unless the benefit outweighs the risk. 
S obzirom na slučajeve teške i po život opasne hepatotoksičnosti opažene u kontroliranim i nekontroliranim studijama, uglavnom u bolesnika s HIV-1 virusnim opterećenjem u plazmi od 50 kopija/ml ili više, primjena nevirapina ne smije se početi u odraslih žena s brojem CD4 većim od 250 stanica/mm3 ili u odraslih muškaraca s brojem CD4 stanica većim od 400 stanica/mm3 koji imaju detektibilan HIV 1-RNK u plazmi,
Female gender and higher CD4 counts at the initiation of nevirapine therapy in treatment-naïve patients is associated with increased risk of hepatic adverse reactions. 
Žene i povišen broj CD4 na početku terapije nevirapinom, prethodno neliječenih, povezan je s povećanim rizikom nastanka jetrenih nuspojava.
Nevirapine Cmin ↑ 1.28 
Nevirapin Cmin ↑ 1,28
Data concerning the pharmacokinetics of nevirapine have been derived from two major sources: a 48 week paediatric study in South Africa (BI 1100.1368) involving 123 HIV-1 positive, antiretroviral naïve patients aged 3 months to 16 years; and a consolidated analysis of five Paediatric AIDS Clinical Trials Group (PACTG) protocols comprising 495 patients aged 14 days to 19 years. 
Južnoj Africi (BI 1100.1368) u koje je bilo uključeno 123 HIV-1-pozitivna, antiretrovirusno prethodno neliječena bolesnika u dobi od 3 mjeseca do 16 godina; i skupna analiza pet studija iz programa pedijatrijskih kliničkih ispitivanja AIDS-a (PACTG), uključujući protokole 495 bolesnika u dobi od
Blood and lymphatic system disorders Common granulocytopenia Uncommon anaemia 
Poremećaji krvi i limfnog sustava Često granulocitopenija
Nevirapine Cmin ↑ 1.07 
Nevirapin Cmin ↑ 1,07
The concomitant administration of Nevirapine Teva with NNRTIs is not recommended (see section 
Istodobna primjena Nevirapina Teva s NNRTI-ima se ne preporučuje
Nevirapine should not be used in patients with severe hepatic impairment (Child-Pugh C, see section 4.3). 
Nevirapin se ne smije primjenjivati u bolesnika s teškim oštećenjem jetre (Child-Pugh C, vidjeti dio 4.3.).
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking Nevirapine Teva. 
Ako Vam je liječnik rekao da ne podnosite neke šećere, javite se liječniku prije početka primjene
Because of the risk of increased exposure to Nevirapine Teva, caution should be exercised if the medicinal products are given concomitantly and patients should be monitored closely. 
Nevirapinu Teva, nužan je oprez ako se lijekovi primjenjuju istodobno, a bolesnici se moraju pomno pratiti.
Maraviroc Cmin ND Maraviroc Cmax ↔ 1.54 (0.94-2.52) compared to historical controls 
Maravirok AUC ↔ 1,01 (0,6 -1,55) Maravirok Cmin NO Maravirok Cmax ↔ 1,54 (0,94-2,52) u usporedbi s povijesnom kontrolom
In the multinational 2NN study, a population pharmacokinetic substudy of 1,077 patients was performed that included 391 females. 
Podaci za 1077 bolesnika (391 žena) uključenih u multinacionalnu studiju 2NN iskorišteni su za populacijsku farmakokinetsku analizu.
Dosing of nevirapine at 150 mg/m2 BID (after a two-week lead in at 150 mg/m2 QD) produced geometric mean or mean trough nevirapine concentrations between 4-6 μg/ml (as targeted from adult data). 
Doziranje 150 mg/m2 dvaput dnevno (nakon uvodna dva tjedna s dozom od 150 mg/m2 jednom dnevno) omogućilo je prosječne koncentracije na kraju dozirnog intervala u rasponu od 4 do 6 µg/ml
No significant effect on rifabutin and nevirapine mean PK parameters is seen. 
Bez značajnog učinka na rifabutin i srednje vrijednosti PK parametara nevirapina.
Nevirapine Teva 200 mg tablets 
Nevirapin Teva 200 mg tablete
Furthermore, in the case nevirapine is used as single dose to prevent vertical transmission of HIV-1 infection, the risk of hepatotoxicity in mother and child cannot be excluded. 
Nadalje, u slučaju kada se nevirapin primjenjuje kao jednokratna doza radi prevencije vertikalnog prijenosa infekcije HIV-om 1,
Nevirapine Teva 200 mg tablets nevirapine 
Nevirapin Teva 200 mg tablete nevirapin
You must take the dose of Nevirapine Teva as prescribed by your doctor. 
Nevirapin Teva uzimajte u dozama koje je propisao liječnik.
Clarithromycin 500 mg BID 
Klaritromicin 500 mg 2x/dan
Significantly fewer patients in the abacavir group (9 patients, or 6%) than in the nevirapine group (26 patients, or 17%) or the efavirenz group (27 patients, or 17%) discontinued the medicinal product because of adverse events. 
(26 bolesnika ili 17%) ili skupini na efavirenzu (27 bolesnika ili 17%) prekinulo je uzimanje lijeka zbog nuspojava (vidjeti donju tablicu).
Nevirapine must not be administered to patients with pretreatment ASAT or ALAT > 5 ULN until baseline ASAT/ALAT are stabilised < 5 ULN (see section 
Nevirapin se ne smije primjenjivati na bolesnicima koji imaju AST ili ALT >5 x GGN prije početka liječenja sve dok se vrijednosti AST/ALT ne stabiliziraju na razini <
How to store Nevirapine Teva 
Kako čuvati Nevirapin Teva
No observable teratogenicity was detected in reproductive studies performed in pregnant rats and rabbits (see section 5.3). 
Reproduktivna ispitivanja na gravidnim ženkama štakora i kunića nisu ukazala na teratogeni potencijal (vidi dio 5.3.).
It is not recommended to coadminister fosamprenavir and Nevirapine Teva if fosamprenavir is not co-administered with ritonavir (see section 4.4). 
Ne preporučuje se istodobna primjena fosamprenavira i Nevirapina Teva, ako se fosamprenavir ne primjenjuje u kombinaciji istodobno s ritonavirom (vidjeti dio 4.4).
However, patients should be advised that they may experience adverse reactions such as fatigue during treatment with Nevirapine Teva. 
Međutim, bolesnike treba upozoriti da tijekom liječenja Nevirapinom Teva mogu dobiti nuspojave, kao što je umor.
Nevirapine must be permanently discontinued in any patient experiencing hypersensitivity reaction (characterised by rash with constitutional symptoms, plus visceral involvement, such as hepatitis, eosinophilia, granulocytopenia, and renal dysfunction), see section 4.4. 
Primjena nevirapina se mora trajno prekinuti u svakog bolesnika kod kojeg se pojavi reakcija preosjetljivosti (karakterizirana osipom s općim simptomima, uz visceralne poremećaje, kao što su hepatitis, eozinofilija, granulocitopenija i disfunkcija bubrega),
Recommendations concerning co-administration 
Preporuke s obzirom na istodobnu primjenu
Nevirapine exhibited additive to synergistic anti-HIV-1 activity in combination with the protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, saquinavir and tipranavir, and the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir and zidovudine. 
amprenavirom, atazanavirom, indinavirom, lopinavirom, sakvinavirom i tipranavirom te s NRTI-ima, abakavirom, didanozinom, emtricitabinom, lamivudinom, stavudinom, tenofovirom i zidovudinom rezultiraju aditivnim do sinergističkom antivirusnom aktivnošću.
Didanosine 100-150 mg BID 
Didanozin 100-150 mg 2x/dan
For children under 16 years of age who weigh less than 50 kg or whose body surface area is below 1.25 m2 other nevirapine containing oral formulations are available and should be used if appropriate. 
Za bolesnike koji ne mogu progutati tabletu ili koji imaju tjelesnu masu manju od 50 kg ili čija je površina tijela ispod 1.25 m2 prema Mosteller formuli, trebali bi uzeti neke druge dostupne oralne oblike koji sadrže djelatnu tvar nevirapin.
Entecavir is not a substrate, inducer or an inhibitor of cytochrome P450 (CYP450) enzymes. 
Entekavir nije supstrat, induktor ili inhibitor enzima citokroma P450
The NEFA study is a controlled prospective randomised study which evaluated treatment options for patients who switch from protease inhibitor (PI) based regimen with undetectable load to either nevirapine, efavirenz or abacavir. 
NEFA je prospektivno, randomizirano kontrolirano ispitivanje koje je uspoređivalo opcije liječenja za bolesnike koji su s prethodnog liječenja inhibitorima proteaza prebačeni na nevirapin, efavirenz ili abakavir, a pri tome su imali nedetektabilno opterećenje virusa u plazmi.
- The other ingredients are microcrystalline cellulose, lactose monohydrate, povidone K25, sodium starch glycolate (Type A), colloidal silicon dioxide and magnesium stearate. 
Pomoćne tvari celuloza, mikrokristalična laktoza (u obliku hidrata) povidon K25 natrijev škroboglikolat (vrste A) silicijev dioksid, koloidni magnezijev stearat
ANTIFUNGALS 
ANTIFUNGICI
If it has been more than 8 hours since the dose was due only take the next dose at the usual time. 
Ako primijetite nakon više od 8 sati kad ste trebali uzeti dozu, uzmite sljedeću dozu u uobičajeno vrijeme.
Female gender and higher CD4 counts (>250/mm in adult females and >400/mm in adult males) at the initiation of nevirapine therapy are associated with a greater risk of hepatic adverse reactions if the patient has detectable plasma HIV-1 RNA - i.e. a concentration ≥ 50 copies/ml - at the initiation of nevirapine. 
250/mm3 u odraslih žena i >400/mm3 u odraslih muškaraca) imaju na početku terapije nevirapinom i povišeni rizik jetrenih reakcija ako pri tome bolesnici imaju HIV-1 RNK u plazmi
ANTITHROMBOTICS 
ANTITROMBOTICI
Atazanavir/r Cmin ↓ 0.28 (0.20-0.40) Atazanavir/r Cmax ↓ 0.72 (0.60-0.86) 
Atazanavir/r AUC ↓ 0,58 (0,48-0,71) Atazanavir/r Cmin ↓ 0,28 (0,20-0,40) Atazanavir/r Cmax ↓ 0,72 (0,60-0,86)
Clarithromycin Cmin ↓ 0.44 (0.30Clarithromycin Cmax ↓ 0.77 (0.69 
Klaritromicin AUC ↓ 0,69 (0,62-0,76) Klaritromicin Cmin ↓ 0,44 (0,30-0,64) Klaritromicin Cmax ↓ 0,77 (0,69-0,86)
Rifabutin Cmin ↔ 1.07 (0.84-1.37) Rifabutin Cmax ↑ 1.28 (1.09-1.51) 
Rifabutin AUC ↑ 1,17 (0,98-1,40) Rifabutin Cmin ↔ 1,07 (0,84-1,37) Rifabutin Cmax ↑ 1,28 (1,09-1,51)
Ketoconazole 400 mg QD 
Ketokonazol 400 mg 1x/dan
Zidovudine AUC ↓ 0.72 (0.60-0.96) 
Zidovudin AUC ↓ 0,72 (0,60-0,96)
Very common (may affect more than 1 in 10 people): - rash 
Manje često (mogu se javiti do 1 od 100 osoba):
During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. 
Metabolički parametri Tijekom antiretrovirusne terapije mogu se povećati tjelesna težina i razine lipida i glukoze u krvi
If you develop severe liver, skin or hypersensitivity reactions whilst taking Nevirapine Teva, NEVER TAKE Nevirapine Teva again without referring to your doctor. 
Ako razvijete teške jetrene, kožne ili reakcije preosjetljivosti dok uzimate Nevirapin Teva,
Darunavir Cmin ↔ 1.02 (0.79-1.32) Darunavir Cmax ↑ 1.40 (1.14-1.73) 
Darunavir AUC ↑ 1,24 (0,97-1,57) Darunavir Cmin ↔ 1,02 (0,79-1,32) Darunavir Cmax ↑ 1,40 (1,14-1,73)
Rifampicin 600 mg QD 
Rifampicin 600 mg 1x/dan
Ritonavir Cmin ↔ 0.93 (0.76-1.14) Ritonavir Cmax ↔ 0.93 (0.78-1.07) 
Ritonavir AUC↔ 0,92 (0,79-1,07) Ritonavir Cmin ↔ 0,93 (0,76-1,14) Ritonavir Cmax ↔ 0,93 (0,78-1,07)
You should continue to take Nevirapine Teva for as long as instructed by your doctor. 
Nevirapine Teva potrebno je uzimati onoliko dugo koliko Vam je rekao liječnik.
EE AUC ↓ 0.80 (0.67 - 0.97) 
EE AUC ↓ 0,80 (0,67 - 0,97) EE Cmin NO
Methadone-maintained patients beginning Nevirapine Teva therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly. 
Nevirapinom Teva treba pratiti radi znakova apstinencije te sukladno tome prilagoditi dozu metadona.
Efavirenz Cmin ↓ 0.68 (0.65-0.81) Efavirenz Cmax ↓ 0.88 (0.77-1.01) 
Efavirenz AUC ↓ 0,72 (0,66-0,86) Efavirenz Cmin ↓ 0,68 (0,65-0,81) Efavirenz Cmax ↓ 0,88 (0,77-1,01)
As hepatotoxicity is more frequent in women with CD4 cell counts above 250 cells/mm3 with detectable HIV-1 RNA in plasma (50 or more copies/ml), 
S obzirom da je hepatotoksičnost češća u žena s brojem CD4 stanica iznad 250 stanica/mm3 s detektabilnim HIV-1 RNK u plazmi (50 ili više kopija/mL), ova stanja moraju biti uzeta u obzir prilikom odluke o terapiji (vidjeti dio 4.4.).
or anaphylactic shock - decreased numbers of red blood cells (anaemia) - yellow skin (jaundice) - severe and life-threatening skin rashes (Stevens-Johnson syndrome/toxic epidermal necrolysis) - hives (urticaria) - fluid under the skin (angioedema) - joint pain (arthralgia) - muscle pain (myalgia) - decreased blood phosphorus - increased blood pressure 
- smanjenjenje broja crvenih krvnih stanica (anemija) - žuta koža (žutica) - teški i po život opasni osipi kože (Stevens-Johnsonov sindrom/toksična epidermalna nekroliza)
Amprenavir Cmin ↓ 0.65 (0.49-0.85) Amprenavir Cmax ↓ 0.75 (0.63-0.89) 
Amprenavir AUC ↓ 0,67 (0,55-0,80) Amprenavir Cmin ↓ 0,65 (0,49-0,85) Amprenavir Cmax ↓ 0,75 (0,63-0,89)
It is not recommended to coadminister ketoconazole and Nevirapine Teva (see section 4.4). 
Ne preporučuje se istodobna primjena ketokonazola i Nevirapina Teva (vidjeti dio 4.4.).
Itraconazole Cmin ↓ 0.13 Itraconazole Cmax ↓ 0.62 
Itrakonazol AUC ↓ 0,39 Itrakonazol Cmin ↓ 0,13
Read the package leaflet before use. 
NAČIN I PUT(EVI) PRIMJENE Prije uporabe pročitajte Uputu o lijeku.
In ACTG 245, a double-blind placebo controlled study, the frequency of serious medicinal product-related granulocytopenia was 5/305 (1.6 %). 
učestalost teške granulocitopenije povezane s lijekom bila je 5/305 (1,6%).
It is not recommended to coadminister boceprevir and Nevirapine Teva (see section 4.4). 
Ne preporučuje se istodobna primjena boceprevira i Nevirapina Teva (vidjeti dio 4.4).
TEVA UK Ltd Brampton Road, Hampden Park, 
TEVA UK Ltd Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Velika Britanija
In a retrospective review of predominantly patients with a plasma HIV-1 viral load of 50 copies/ml or higher, women with CD4 counts > 250 cells/mm3 had a 12 fold higher risk of symptomatic hepatic adverse reactions compared to women with CD4 counts < 250 cells/mm3 (11.0 % 
U retrospektivnom pregledu uglavnom bolesnika s HIV-1 virusnim opterećenjem od 50 kopija/ml ili više u plazmi, žene s brojem CD4 >250 stanica/mm3
Each tablet contains 200 mg nevirapine (as nevirapine anhydrate). 
Svaka tableta sadrži 200 mg nevirapina (u bezvodnom obliku).
NET AUC ↓ 0.81 (0.70 - 0.93) 
NET AUC ↓ 0,81 (0,70 - 0,93) NET Cmin NO
NNRTIs Efavirenz 600 mg QD 
NNRTI-i Efavirenz 600 mg 1x/dan
Zidovudine Cmin ND Zidovudine Cmax ↓ 0.70 (0.49-1.04) 
100-200 mg 3x/dan Zidovudin Cmin NO Zidovudin Cmax ↓ 0,70 (0,49-1,04)